QID 377598

Date Published: 2022-09-20

QID 377598: Mozilla Thunderbird Multiple Vulnerabilities (MFSA2022-39)

Thunderbird is a free and open-source cross-platform email client developed for Windows, OS X, and Linux, with a mobile version for Android.

Mozilla Thunderbird is prone to
CVE-2022-3033: Leaking of sensitive information when composing a response to an HTML email with a META refresh tag
CVE-2022-3032: Remote content specified in an HTML document that was nested inside an iframe's srcdoc attribute was not blocked
CVE-2022-3034: An iframe element in an HTML email could trigger a network request

Affected Products:
Prior to Mozilla Thunderbird 91.13.1

QID Detection Logic (Authenticated) :
This checks for vulnerable version of Thunderbird.


Note: The preceding description block is extracted directly from the security advisory. Using automation, we have attempted to clean and format it as much as possible without introducing additional issues.

Successful exploitation of this vulnerability could lead to a security breach or could affect integrity, availability, and confidentiality.

  • CVSS V3 rated as Critical - 8.6 severity.
  • CVSS V2 rated as Medium - 5.4 severity.
    • Solution
    Vendor has released fix to address these vulnerabilities. Refer to MFSA2022-39 or later
    Vendor References

    CVEs related to QID 377598

    CVE-2022-3034 | CVE-2022-3033 | CVE-2022-3032 |
    Software Advisories
    Advisory ID Software Component Link
    MFSA2022-39 URL Logo www.mozilla.org/en-US/security/advisories/mfsa2022-39/
    By selecting these links, you may be leaving CVEreport webspace. We have provided these links to other websites because they may have information that would be of interest to you. No inferences should be drawn on account of other sites being referenced, or not, from this page. There may be other websites that are more appropriate for your purpose. CVEreport does not necessarily endorse the views expressed, or concur with the facts presented on these sites. Further, CVEreport does not endorse any commercial products that may be mentioned on these sites. Please address comments about any linked pages to [email protected].